EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

MRI use prior to prostate biopsy after guideline recommendation in Canada

Jacob Bennett, Tarana A. Mangukia, Eden Philips, Tarana Mangukia, Tark Patel, Parsa Babaei Zadeh, Melis Guer, Adam Kinnaird

Canadian Urological Association Journal · 2026-10-19 · 21 (2)

DOI: 10.5489/cuaj.9701 ↗
AstrattDettalji biblijografiċi

Astratt

Introduction: Implementation of magnetic resonance imaging (MRI) prior to a prostate biopsy has improved detection of clinically significant prostate cancer, while reducing overdiagnosis of low-risk disease. Accordingly, the Canadian Urological Association (CUA) updated its prostate screening guidelines to recommend MRI prior to prostate biopsy in biopsy-naive men in 2022. This study aims to assess real-world implementation of pre-biopsy MRI by urologists in accordance with CUA guidelines. Methods: We conducted a retrospective, observational cohort study of all men undergoing prostate biopsy from April 2022 to April 2024 in Edmonton, AB, Canada. Data was extracted from a province-wide electronic medical record. Inclusion criteria were biopsy-naive men with a prostate-specific antigen (PSA) ≤20 ng/ml. Statistical analysis completed using Chi-squared and two-proportioned z-tests. Results: A total of 2626 men underwent prostate biopsy during the study period and 1491 participants met the inclusion criteria; 1054 (71%) received MRI prior to biopsy, with a median wait time to MRI of 101 days (interquartile range [IQR] 30–164). Inclusion of MRI in the diagnostic pathway was significantly associated with a longer interval from initial urology consultation to prostate biopsy (208 vs. 52 days, p

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →